Skip to main content
SpringerLink
Log in

Biologic response modifiers in the management of superficial bladder cancer

  • Published:
World Journal of Urology Aims and scope Submit manuscript

Summary

For the treatment of existing transitional-cell carcinoma or for prophylaxis of recurrent disease, intravesical therapy should be chosen according to stage. Papillary disease (stages Ta, TI) may be treated effectively either with an alkylating agent or with bacillus Calmette-Guérin (BCG). BCG is the agent of choice for the treatment of Hat carcinoma in situ (Tis), with the recommended treatment course comprising 12 weekly and 12 monthly instillations. Intravesical interferon and many of the other biologic response modifiers mentioned herein may be effective for patients with Ta disease who have failed BCG therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Akaza H, Hinotsu S, Aso Y, et al (1995) BCG alone as treatment of superficial bladder cancer: can TURBT be avoided (abstract 23)? J Urol 153 [Suppl]: 234A

  2. Althausen AF, Prout GR Jr, Daly JJ (1976) Non-invasive papillary carcinoma of the bladder associated with carcinoma in situ. J Urol 116: 575–580

    Google Scholar 

  3. Aso Y, Akazan H (1992) Prophylactic effect of aLactobacillus casei preparation on the recurrence of superficial bladder cancer. BLP study group. Urol Int 49: 125–129

    Google Scholar 

  4. Badalament RA, Herr HW, Wong GY, et al (1987) A prospective randomized trial of maintenance versus maintenance intravesical Bacillus Calmette-Guerin therapy of superficial bladder cancer. J Clin Oncol 5: 441–449

    Google Scholar 

  5. Boccardo F, Cannata D, Rubagotti A, Guarneri D, Decensi A, Canobbio L, et al (1994) Prophylaxis of superficial bladder cancer with mitomycin or interferon alpha-2b: results of a multicentric Italian study. J Clin Oncol 12: 1–4

    Google Scholar 

  6. Bohle A, Nowc C, Ulmer AJ, et al (1990) Elevations of cytokines interleukin-1, interleukin-2 and tumor necrosis factor in the urine of patients after intravesical bacillus Calmette-Guerin immunotherapy. J Urol 144: 59–64

    Google Scholar 

  7. Brosman SA (1997) Indications for BCG use in carcinoma in situ. Urology 37 [Suppl]: 12–15

    Google Scholar 

  8. Brosman SA, Lamm DL (1990) The preparation, handling and use of intravesical bacillus Calmette-Guérin for the management of stage Ta, TI, carcinoma in situ and transitional cell cancer. J Urol 144: 313–315

    Google Scholar 

  9. Carballido J, Molto LM, Olivier C, Manzano L (1992) Analysis of the effect of intravesical treatment with interferon-alpha 2b on the clinical evolution and on the in vivo function of T lymphocytes and natural killer cells in patients with superficial bladder tumors. Anticancer Drugs 3: 9–12

    Google Scholar 

  10. Catalona WJ (1992) Urothelial tumors of the urinary tract. In: Walsh P, Retik A, Stamey T, Vaughan DE (eds): Camptelli Urology. Saunders, Philadelphis. pp 1094–1154

    Google Scholar 

  11. Catalona WJ, Hudson MA, Gillen DP, et al (1987) Risks and benefits of repeated courses of bacillus Calmette-Guérin therapy for superficial bladder cancer. J Urol 137: 220–224

    Google Scholar 

  12. Cheng DL, Shu WP, Choi JC, Margolis EJ, Droller MJ, Liu BC (1994) Bacillus Calmette-Guérin interacts with the carboxyl-terminal heparin binding domain of fibronectin: implications for BCG-mediated antitumor activity. J Urol 1524: 1275–1280

    Google Scholar 

  13. Coplen DE, Marcus MD, Myers JA, et a1 (1990) Long-term follow-up of patients treated with 1 or 2, 6-week courses of intravesical Bacillus Calmette-Guérin: analysis of possible predictors of response free of tumor. J Urol 144: 652–657

    Google Scholar 

  14. De Boer SC, Van Brumnelen D, Kurth K-H, et al (1996) Chemotactic activity of bacillus Calmette-Guérin (BCG) released product(s) (abstract 1033), J Urol 155 [suppl]: 569A

  15. Dinney CPN, Fidler IJ, Eve B, et al (1994) Therapy of human transitional cell carcinoma in an orthotopic murine model of superficial bladder carcinoma by the macrophage activator MLV-CGP-19835 (abstract 1151). J Urol 151 [suppl]: 515A

  16. Di Stasi SM, Virgili G, Vespasiani G, Porena M, Micali F (1993) Intralesional alpha interferon therapy in papillary superficial transitional cell carcinoma of the bladder. A pilot study. Br J Urol 71: 422–426

    Google Scholar 

  17. Erol A, Ozgur S, Basar M, Cetin S (1994) Trial with bacillus Calmette-Guérin and epirubicin combination in prophylaxis of superficial bladder cancer. Urol Int 52: 69–72

    Google Scholar 

  18. Esuvaranathan K, Alexandroff AB, McIntyre M, et al (1994) Interleukin-6 production by bladder tumors is upregulated by BCG immunotherapy (abstract 1153). J Urol 151 [suppl]: 516A

  19. Eure GR, Cundiff MR, Schellhammer PF (1992) Bacillus Calmette-Guérin therapy for high risk stage T1 superficial bladder cancer. J Urol 147: 376–379

    Google Scholar 

  20. Ferlazzo G, Magno C, Lupo G, Rizzo M, Iemmo R, Semino C, Melioli G (1995) A phase I study of intravesical continuous perfusion of recombinant interleukin-2 in patients with superficial bladder cancer. Am J Clin Oncol 18: 100–104

    Google Scholar 

  21. Ferrari P, Castagnetti G; Pollastri CA, Ferrari G, Tavoni F, Grassi D (1992) Chemoimmunotherapy for prophylaxis of recurrence in superficial bladder cancer: interferon-alpha 2b versus interferon-alpha 2b with epirubicin. Anticancer Drugs 3: 25–27

    Google Scholar 

  22. Flamm J, Bucher A, Holtl W, et al (1990) Recurrent transitional cell carcinoma of the bladder: adjuvant topical chemotherapy versus immunotherapy. A prospective randomized trial. J Urol 144: 260–263

    Google Scholar 

  23. Fleischmann JD, Toossi Z, Ellner JJ, et al (1989) Urinary interleukins in patients receiving intravesical bacillus Calmette-Guérin therapy for superficial bladder cancer. Cancer 64: 1447–1454

    Google Scholar 

  24. Fleischmann JD, Shingleton WB, Gallagher C, et al (1991) Fibrinolysis, thrombocytopenia and coagulation abnormalities complicating high-dose interleukin-2 immunotherapy. J Lab Clin Med 117: 76–82

    Google Scholar 

  25. Fleischmann J, Park M, Hassan M (1993) Fibronectin (FN) concentration in normal mucosa associated with bladder cancer predicts response to intravesical BCG. J Urol 149: 268–271

    Google Scholar 

  26. Glashan RW (1990) A randomized controlled study of intravesical alpha-2b-interferon in carcinoma in situ of the bladder. J Urol 144: 658–661

    Google Scholar 

  27. Glazier DB, Bahnson RR, McLeod DG, Roemeling RW von, Messing EM, Ernstoff MS (1995) Intravesical recombinant tumor necrosis factor in the treatment of superficial bladder cancer: an Eastern Cooperative Oncology Group study. J Urol 154: 66–68

    Google Scholar 

  28. Grampsas SA, Kahn K, Crawford ED (1994) Intravesical RTNF therapy of superficial bladder cancer. A phase I study of recombinant tumor necrosis factor administered intravesically to patients with superficial bladder cancer. On-line Curr Clin Trials 117: 1994

    Google Scholar 

  29. Herr HW, Pinsky CM Whitmore WF Jr, et al (1986) Long term effect of intravesical bacillus Calmette-Guérin on flat carcinoma in situ of the bladder. J Urol 135: 265–267

    Google Scholar 

  30. Herr HW, Laudone VP, Badalament RA, et al (1988) Bacillus Calmette-Guérin therapy alters the progression of superficial bladder cancer. J Clin Oncol 6: 1450–1455

    Google Scholar 

  31. Herr HW, Wartinge DD, Fair WR, et al (1992) Bacillus Calmette-Guérin therapy for superficial bladder cancer: a 10 year follow-up. J Urol 147: 1020–1023

    Google Scholar 

  32. Hoeltl W, Hasun R, Albrecht W, et al (1991) How effective is topical alpha-2b interferon in preventing recurrence of superficial bladder cancer? Br J Urol 68: 495–498

    Google Scholar 

  33. Hudson MA, Yuan JJ, Catalona WJ, et al (1990) Adverse impact of fibrin clot inhibitors on intravesical bacillus Calmette-Guérin therapy for superficial bladder tumors. J Urol 144: 1362–1364

    Google Scholar 

  34. Isaacs H, Lindenmann J (1957) Virus interference. 1. The interferons. Proc R Soc Lond (Biol) 147: 258–273

    Google Scholar 

  35. Itri LM (1992) The interferons. Cancer 70 [Suppl]: 940–945

    Google Scholar 

  36. Jansson O, Adolfsson J, Wiklund NP (1996) BCG treatment of superficial bladder cancer induces nitric oxide synthase activity (abstract 1034). J Urol 155 [suppl]: 569A

  37. Jurincic CD, Engelmann U, Gasch J, et al (1988) Immunotherapy in bladder cancer with keyhole-limpet hemocyanin: a randomized study. J Urol 139: 723

    Google Scholar 

  38. Klimberg IW, Pow-Sang JM, Cartwright CK, et al (1991) Intravesical bacillus Calmette-Guérin for patients with high-risk superficial bladder cancer. Urology 37: 180–184

    Google Scholar 

  39. Kunkler RB, Bishop MC, Green DJ, Pimm MV, Price MR, Frier M (1995) Targeting of bladder cancer with monoclonal antibody NCRC48 — a possible approach for intravesical therapy. Br J Urol 76: 81–86

    Google Scholar 

  40. Lamm DL (1984) Editorial comment. J Urol 132: 676

    Google Scholar 

  41. Lamm DL, Reyna JA, Reichaert DF (1987) Keyhole-limpet haemocyanin and immune ribonucleic acid immunotherapy of murine transitional cell carcinoma. Urol Res 9: 227–229

    Google Scholar 

  42. Lamm DL, Thor DE, Winters WD, et al (1981) BCG immunotherapy of bladder cancer: inhibition of tumor recurrence and associated immune responses. Cancer 48: 82–88

    Google Scholar 

  43. Lamm DL, Griffith G, Pettit LL, et al (1992) Current perspectives on diagnosis and treatment of superficial bladder cancer. Urology 39: 301–308

    Google Scholar 

  44. Lamm DL, Van Der Meijden APM, Morales A, et al (1992) Incidence and treatment of complications of bacillus Calmette-Guérin intravesical therapy in superficial bladder cancer. J Urol 147: 596–600

    Google Scholar 

  45. Lerman RI, Flutter VP, Whitmore WF Jr (1970) Papilloma of the urinary bladder. Cancer 25: 333–342

    Google Scholar 

  46. Lotzova E, Savary CA, Stringfellow DA (1983) 5-Halo-6phenyl-pyrimidinones: new molecules with cancer chemotherapeutic potential and interferon-inducing capacity are strong induces of murine natural killer cells. J Immunol 130: 965–969

    Google Scholar 

  47. Lotzova E, Savary CA, Khan A, Stringfellow DA (1984) Stimulation of natural killer cells in two random-bred strains of athymic rats by interferon-inducing pyrimidinone. J Immunol 132: 2566–2570

    Google Scholar 

  48. Lutzeyer W, Rubben H, Dahm H (1982) Prognostic parameters of superficial bladder cancer: an analysis of 315 cases J Urol 127: 250–252

    Google Scholar 

  49. Mack D, Frick J (1995) Low-dose bacillus Calmette-Guérin (BCG) therapy in superficial high-risk bladder cancer: a phase 11 study with the BCG strain Connaught Canada. Br J Urol 75: 185–187

    Google Scholar 

  50. Mack D, Frick J (1995) Five-year results of a phase II study with low-dose bacillus Calmette-Guérin therapy in high-risk superficial bladder cancer. Urology 45: 958–961

    Google Scholar 

  51. Martinez-Pineiro JA, Solsona E, Flores N, Isorna S (1995) Improving the safety of BCG immunotherapy by dose reduction. Cooperative Group CUETO. Eur Urol 27 [Suppl 1]: 1318

    Google Scholar 

  52. Merguerian PA, Donahue LA, Cockett ATK (1987) Intraluminal interleukin-2 and bacillus Calmette-Guérin for treatment of bladder cancer. J Urol 137: 216–219

    Google Scholar 

  53. Merz VW, Ackermann DK, Studer UE, et al (1994) Intravesical BCG instillation therapy for superficial papillary bladder tumors of stage T1 (abstract 990). J Urol 151 [suppl]: 475A

  54. Merz VW, Marth D, Kraft R, Ackermann DK, Zingg EJ, Studer UE (1995) Analysis of early failures after intravesical instillation therapy with bacillus Calmette-Guérin for carcinoma in situ of the bladder. Br J Urol 75: 180–184

    Google Scholar 

  55. Migliari R, El Demiry M, Muscas G, Usai E (1992) Intravesical instillation of beta-interferon in the treatment of bladder cancer. Br J Urol 70: 169–173

    Google Scholar 

  56. Molto L, Alvarez-Mon M, Carballido J, Olivier C, Gimeno F, Manzano L (1995) Use of intracavitary interferon alpha-2b in the prophylactic treatment of patients with superficial bladder cancer. Cancer 75: 2720–2726

    Google Scholar 

  57. Nadler RB, Catalona WJ, Hudson MA, Ratliff TL (1994) Durability of the tumor-free response for intravesical bacillus Calmette-Guérin therapy. J Urol 152: 367–373

    Google Scholar 

  58. Nadler RB, Ritchey JK, Gerber AJ, et al (1995) Effects of interleukin-10 on BCG-induced antitumor activity (abstract 1042). J Urol 153 [suppl]: 489A

  59. Netto NR Jr, Lemos GC (1984) Bacillus Calmette-Guérin immunotherapy of infiltrating bladder cancer. J Urol 132: 675–677

    Google Scholar 

  60. Ogden C, Sandle gnJ, Fisher gnC, et al (1996) Monoclonal antibody targeting of bladder cancer (abstract 1031). J Urol 155 [suppl]: 568A

  61. Pagano F, Bassi P, Milani C, Meneghini A, Maruzzi D, Garbellio A (1991) A low dose bacillus Calmette-Guérin regimen in superficial bladder cancer therapy — is it effective? J Urol 146: 32–35

    Google Scholar 

  62. Pansadoro V, DePaula F (1987) Intravesical bacillus Calmette-Guérin in the treatment of superficial transitional cell carcinoma of the bladder. J Urol 138: 299–301

    Google Scholar 

  63. Pansadoro V, Emiliozzi P, Defidio L, Donadio D, Florio A, Maurelli S, Lauretti S, Sternberg CN (1995) Bacillus Calmette-Guérin in the treatment of stage TI grade 3 transitional cell carcinoma of the bladder: long-term results. J Urol 154: 2054–2058

    Google Scholar 

  64. Pizza G, Sevanni G, Menniti D, et al (1984) Tumor regression after intralesional injection of interleukin-2 (IL-2) in bladder cancer. Preliminary report. Int J Cancer 34: 359–367

    Google Scholar 

  65. Prout GR Jr, Barton BA (1992) 13-cis-Retinoic acid in chemoprevention of superficial bladder cancer. The National Bladder Cancer Group. J Cell Biochem 161 [Suppl]: 148–152

    Google Scholar 

  66. Prom GR Jr, Griffin PP, Daly JJ, et al (1983) Carcinoma in situ of the urinary bladder with and without associated vesical neoplasms. Cancer 52: 524–532

    Google Scholar 

  67. Raitanen MP, Lukkarinen O (1995) A controlled study of intravesical epirubicin with or without alpha 2b-interferon as prophylaxis for recurrent superficial transition cell carcinoma of the bladder. Br J Urol 76: 697–701

    Google Scholar 

  68. Ratliff TL, Kavoussi LR, Catalona WJ (1988) Role of fibronectin in intravesical BCG therapy for superficial bladder cancer. J Urol 139: 410–414

    Google Scholar 

  69. Rawls WH, Lamm DL, Lowe BA, Crawford ED (1990) Fatal sepsis following intravesical BCG administration for bladder cancer. J Urol 144: 1328

    Google Scholar 

  70. Riggs DR, Dehaven JI, Lamm DL (1996)Lactobacillus casei (LC) immunotherapy of murine bladder cancer (MBT2) (abstract 35). J Urol 155 [Suppl]: 319A

  71. Rogerson JW (1994) Intravesical bacillus Calmette-Guérin in the treatment of patients with superficial transitional cell carcinoma of the bladder. Br J Urol 73: 655–658

    Google Scholar 

  72. Rosenbaum RS, Park MC, Fleischmann J (1996) Intravesical bacillus Calmette-Guérin therapy for muscle invasive bladder cancer. Urology 47: 208–211

    Google Scholar 

  73. Rosenberg SA, Lotze MT, Muul LM (1987) A progress report of treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316: 889–897

    Google Scholar 

  74. Russell PJ, Davis K, Kingsley E, et al (1994) Preclinical studies of monoclonal antibodies for intravesical radioimmunotherapy of human bladder cancer. Cell Biophy 24/25: 155–161

    Google Scholar 

  75. Sarosdy MF, Lamm DL (1989) Long-term results of intravesical bacillus Calmette-Guérin therapy for superficial bladder cancer. J Urol 142: 719–722

    Google Scholar 

  76. Sarosdy MF, Lowe BA, Schellhammer PF, et al (1996) Oral bropirimine immunotherapy of carcinoma in situ of the bladder: results of a phase II trial. Urology 48: 21–27

    Google Scholar 

  77. Sarosdy MF, Pisters LL, Carroll PR, et al (1996) Bropirimine immunotherapy of upper urinary tract carcinoma in situ. Urology 48: 28–32

    Google Scholar 

  78. Schwaibold H, Huland E, Heinzer H, Schwulera U, Huland H (1995) Toxicity of local, continuous and cyclic, high-dose bladder perfusion with recombinant and natural interleukin-2 in advanced cancer of the urinary bladder. J cancer Res Clin Oncol 121: 239–246

    Google Scholar 

  79. Soloway MS (1988) Intravesical therapy for bladder cancer. Urol Clin North Am 15: 661–669

    Google Scholar 

  80. Sosnowski JT, DeHaven JI, Riggs DR, et al (1991) Treatment of murine transitional cell carcinoma with intralesional interleukin 2 and murine interferon gamma.J Urol 146: 1164–1167

    Google Scholar 

  81. Tanaka M, Shinchara N, Nagamori S, et al (1994) Prophylactic intravesical instillation of BCG in recurrent superficial bladder cancer: is BCG treatment superior to other chemotherapeutic agents (abstract 990)? J Urol 151 [Suppl]: 475A

  82. Torti FM, Lum BL (1984) The biology and treatment of superficial bladder cancer. J Clin Oncol 2: 505–531

    Google Scholar 

  83. Torti FM, Shortliffe LD, Williams RD, et al (1988) Alpha interferon in superficial bladder cancer: a Northern California Oncology Group study. J Clin Oncol 6: 476–483

    Google Scholar 

  84. Tracey DE, Richard KA (1987) Mechanisms of immunostimulation by pyrimidinones. In: Of infectious diseases: vaccine adjuvants and modulators of nonspecific resistance. Liss, New York, pp 279–289

    Google Scholar 

  85. Utz DC, Hanash KA, Farrow GM (1970) The plight of the patient with carcinoma in situ of the bladder. J Urol 103: 160–164

    Google Scholar 

  86. Wadler S (1992) The role of interferons in the treatment of solid tumors. Cancer 70 [Suppl]: 949–958 1992

    Google Scholar 

  87. Wagner JR, Szilvasi A, Mayor S, et al (1995) BCG strongly induces interleukin-12 production in vitro and in vivo in mouse and man (abstract 1034). J Urol 153 [Suppl]: 487A

  88. Wierenga W (1985) Antiviral and other bioactivities of pyrimidinones. Pharmacol Ther 30: 67–89

    Google Scholar 

  89. Witjes JA, Fransen MP, Meijden AP van der, Doesburg WH, Debruyne FM (1993) Use of maintenance intravesical BCG in patients with recurrent superficial bladder cancer. Long-term follow-up of a randomized phase II study. Urol Int 51: 67–72

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. 2-South-62, Jack D. Weiler Hospital, 1825 Eastchester Road, 10461, Bronx, NY, USA

    Scott Serels (Director of Onoclogic Urology) & Jonathan Fleischmann (Director of Onoclogic Urology)

Authors
  1. Scott Serels
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jonathan Fleischmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Serels, S., Fleischmann, J. Biologic response modifiers in the management of superficial bladder cancer. World J Urol 15, 96–102 (1997). https://doi.org/10.1007/BF02201979

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02201979

Keywords

Search

Navigation